About Us

We bring together agile development and manufacturing capabilities,
with a proven 30+ years' track record of successful supply and consistent reliability, propelled by a comprehensive portfolio
of emergency solutions across a variety of therapeutic areas.

Our Approach

Strategic Partnerships

Partnerships have been the cornerstone of our growth for over 30 years. Examples Include CRADA with the US DoD and a long- term R&D collaboration with the Israeli MoD.

Total Agility

Our wide experience and flexible capabilities enable us to offer tailor-made solutions with a short lead time, from small to large-scale batches.

Highest Quality Standards

Our state-of-the-art manufacturing facility works under strict GMP and GDP guidelines and is ISO accredited.

Key milestones

Discover the key highlights of our remarkable history -
30+ years of extensive experience commencing with the first Gulf War.

1990

Close

Rafa collaborates with the Israeli Ministry of Defense to develop an atropine autoinjector

1991

Vector

Gulf war:


Israeli Ministry of Defense (IMoD) provides Rafa’s atropine autoinjectors to 100% of the Israeli population

1993
Close

Development of atropine & trimedoxime (TA) autoinjector

2003
Vector

Gulf war 2:


Israeli Ministry of Defense (IMoD) provides Rafa’s TA autoinjectors to 100% of the Israeli population

2010
Close

Development of morphine autoinjector

2016
Vector

Rafa signs 5Y supply
agreement for atropine
autoinjector to US Gov

2017
Close

First commercial supply
of atropine autoinjectors
to US Gov (EUA)

2018
Vector

Rafa obtains FDA
approval for atropine
autoinjector

2019
Close

Development of triple
combination autoinjector:
trimedoxime, atropine
& benactyzine

2020
Vector

Development of
midazolam autoinjector & naloxone
autoinjector

2022
Close

Introducing Rafa’s product portfolio to NATO

Close

Rafa obtains FDA approval for midazolam autoinjector, and signs production agreement with US-DoD

2023
Close

Rafa supplies midazolam autoinjector to US-DoD

Close

Rafa signs a new $13m development contract with US DHHS (BARDA) for the improvement of its autoinjector platform, to better address
the civilian population

End-to-End Development and Manufacturing Services

Planning

Check LinkedIn
step 1

Product development

Check LinkedIn
step 2

Commercialization

Check LinkedIn
step 3

Highest International Standards

Meet Our People
Background

Roy Shay

VP Biodefense

Ofir Amar

Biodefense Business Operations Manager

Arik Eisenkraft

Medical Lead

Tzufit Warhaftig

Head of R&D

Marina Zimmerman

Biodefense Project Manager

Background
Vector Layer Vector

News & Updates

The information on this website is intended only for
professionals in the pharmaceutical and CBRN fields.

Are you a specialist in one of these areas?